PRESS RELEASE published on 03/20/2025 at 07:00, 1 year 7 months ago Inside Information / Other news releases Innate Pharma to hold conference call and webcast for full year 2024 financial results on March 27, 2025. Details for participation provided Financial Results Conference Call Biotechnology Webcast Innate Pharma
BRIEF published on 02/17/2025 at 07:07, 1 year 8 months ago Innate Pharma reçoit le statut de "Breakthrough Therapy" de la FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Syndrome De Sézary
BRIEF published on 02/17/2025 at 07:07, 1 year 8 months ago Innate Pharma Receives Breakthrough Therapy Designation from FDA FDA Innate Pharma Breakthrough Therapy Lacutamab Sézary Syndrome
PRESS RELEASE published on 02/17/2025 at 07:02, 1 year 8 months ago Informations privilégiées / Autres communiqués Innate Pharma reçoit le statut de "Breakthrough Therapy" de la FDA pour Lacutamab dans le syndrome de Sézary en rechute ou réfractaire. Accélération du développement réglementaire aux États-Unis FDA Innate Pharma Breakthrough Therapy Lacutamab Syndrome De Sézary
PRESS RELEASE published on 02/17/2025 at 07:02, 1 year 8 months ago Inside Information / Other news releases Innate Pharma receives U.S. FDA Breakthrough Therapy Designation for Lacutamab in Sézary syndrome treatment, showing promising results in Phase 2 TELLOMAK study FDA Innate Pharma Lacutamab Sézary Syndrome Breakthrough Therapy Designation
BRIEF published on 01/27/2025 at 07:05, 1 year 9 months ago Innate Pharma Initiates Phase 1 Study of IPH4502 for Advanced Solid Tumors Phase 1 Trial Innate Pharma IPH4502 Nectin-4 Advanced Solid Tumors
BRIEF published on 01/27/2025 at 07:05, 1 year 9 months ago Innate Pharma lance une étude de phase 1 sur IPH4502 dans les tumeurs solides avancées Innate Pharma Essai De Phase 1 IPH4502 Nectine-4 Tumeurs Solides Avancées
PRESS RELEASE published on 01/27/2025 at 07:00, 1 year 9 months ago Inside Information / Other news releases Innate Pharma announces first patient dosed in Phase 1 study of Nectin-4 targeting Antibody Drug IPH4502 in advanced solid tumors. Innovative ADC for multiple cancer types Innate Pharma Phase 1 Study IPH4502 Topoisomerase I Inhibitor Antibody Drug Conjugate
PRESS RELEASE published on 01/27/2025 at 07:00, 1 year 9 months ago Informations privilégiées / Autres communiqués Innate Pharma annonce le traitement du premier patient dans l'essai de phase 1 évaluant IPH4502, son conjugué anticorps-médicament ciblant Nectine-4, dans une sélection de tumeurs solides avancées Innate Pharma Tumeurs Solides Conjugué Anticorps-médicament IPH4502 Nectine-4
BRIEF published on 01/16/2025 at 07:05, 1 year 9 months ago Nouveau Bilan des Actions et Droits de Vote pour Innate Pharma Droits De Vote AMF Actions Ordinaires Structure Actionnariale Innate Pharma
Published on 10/28/2026 at 12:30, 37 minutes ago Digi Power X to Announce 2026 Q3 Financial Results and Provide Operations Update on November 13th
Published on 10/28/2026 at 12:30, 37 minutes ago AI/ML Innovations Announces Advance Notice Provisions
Published on 10/28/2026 at 12:30, 37 minutes ago Sterling Expands Mineralized Footprint to 2km With Near Surface Intercept in 850m Eastern Step Out
Published on 10/28/2026 at 12:30, 37 minutes ago Ameriwest Reports Additional High-Grade Copper Results from Historical Drill Core at Bornite Including 71.0 Feet (21.6 Meters) at 8.08% CuEq
Published on 10/28/2026 at 12:15, 52 minutes ago BULGOLD Expands Strategic Exploration Position Around the Lutila Gold Project with Two New Exploration Licences
Published on 10/28/2026 at 12:58, 9 minutes ago EQS-Adhoc: Befesa S.A.: Befesa raises FY 2026 adjusted EBITDA guidance to €286–296 million due to expected contribution from Critical Materials US grant of approx. €26 million
Published on 10/28/2026 at 12:24, 43 minutes ago EQS-Adhoc: Ad-hoc | IVU Traffic Technologies AG: Earnings for the first nine months of 2026 were significantly higher than the previous year; full-year guidance reiterated
Published on 10/28/2026 at 12:21, 46 minutes ago HELIOS SOLAR AG Postpones Publication of Audited Annual and Consolidated Financial Statements as of 30 June 2026
Published on 10/28/2026 at 12:05, 1 hour 2 minutes ago Bloomberg Introduces BQuant Assistant to Help Financial Professionals Accelerate Data Analysis and Coding Workflows
Published on 10/28/2026 at 11:49, 1 hour 18 minutes ago OHB and Astroscale sign agreement to strengthen international cooperation on space security and orbital services capabilities
Published on 10/28/2026 at 08:00, 5 hours 7 minutes ago Edenred successfully raises €800 million in a dual-tranche bond offering
Published on 10/28/2026 at 08:00, 5 hours 7 minutes ago Edenred lève avec succès 800 millions d’euros dans le cadre d’une émission obligataire à deux tranches
Published on 10/27/2026 at 18:00, 19 hours 7 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of October 22, 2026
Published on 10/27/2026 at 18:00, 19 hours 7 minutes ago Nombre total de droits de vote et actions composant le capital social au 22 octobre 2026
